Corvus reports symptom improvement in three ALPS patients in Phase 2 soquelitinib trial
CRVS•Three patients in Corvus Pharmaceuticals’ Phase 2 soquelitinib trial for ALPS reported improved disease-related symptoms after one year of treatment. The company said treatment was well tolerated and all three patients discontinued background medications, including steroids.
1. Trial results
Three patients had completed one year of treatment as of August 3, 2026, and reported improvement in disease-related symptoms. Corvus said there were no severe adverse events or treatment interruptions, and all three discontinued background medications, including steroids.
2. Next steps
Corvus plans to present the results at the American Society of Hematology meeting on December 14, 2026. The findings support continued enrollment, with plans to explore longer treatment and include younger pediatric patients.
